V. Heilmann

1.1k total citations
32 papers, 870 citations indexed

About

V. Heilmann is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, V. Heilmann has authored 32 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in V. Heilmann's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (5 papers). V. Heilmann is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (5 papers). V. Heilmann collaborates with scholars based in Germany, Austria and Switzerland. V. Heilmann's co-authors include R. Kreienberg, Hans‐Juergen Brambs, A. Rieber, Thorsten Kühn, Andreas Gabelmann, Magnus von Knebel Doeberitz, Matthias Nees, Matthias Dürst, Ruediger Klaes and Peter Melsheimer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

V. Heilmann

29 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Heilmann Germany	15	342	209	200	186	153	32	870
Delicia Carey United States	15	596 1.7×	221 1.1×	491 2.5×	84 0.5×	71 0.5×	21	1.2k
Masanori Someya Japan	18	348 1.0×	140 0.7×	277 1.4×	149 0.8×	74 0.5×	70	902
Judith Jo Spain	15	508 1.5×	250 1.2×	308 1.5×	149 0.8×	106 0.7×	23	852
V. Fermeaux France	10	400 1.2×	255 1.2×	208 1.0×	86 0.5×	36 0.2×	30	847
Harry Klip Netherlands	21	407 1.2×	54 0.3×	525 2.6×	260 1.4×	291 1.9×	28	1.2k
Petra Kohlberger Austria	20	327 1.0×	74 0.4×	516 2.6×	228 1.2×	187 1.2×	67	1.2k
Renata Tassi Italy	20	341 1.0×	85 0.4×	394 2.0×	244 1.3×	119 0.8×	30	1.3k
Paweł Blecharz Poland	15	358 1.0×	89 0.4×	234 1.2×	309 1.7×	59 0.4×	72	1.0k
Serge Smeets Netherlands	17	400 1.2×	37 0.2×	541 2.7×	306 1.6×	278 1.8×	39	1.4k
Włodzimierz Olszewski Poland	19	476 1.4×	74 0.4×	289 1.4×	409 2.2×	112 0.7×	51	1.1k

Countries citing papers authored by V. Heilmann

Since Specialization

Citations

This map shows the geographic impact of V. Heilmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Heilmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Heilmann more than expected).

Fields of papers citing papers by V. Heilmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Heilmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Heilmann. The network helps show where V. Heilmann may publish in the future.

Co-authorship network of co-authors of V. Heilmann

This figure shows the co-authorship network connecting the top 25 collaborators of V. Heilmann. A scholar is included among the top collaborators of V. Heilmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Heilmann. V. Heilmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dall, Peter, Thomas Göhler, Christian Lerchenmüller, et al.. (2015). Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. Journal of Geriatric Oncology. 6(6). 462–469. 19 indexed citations

Lück, Hans‐Joachim, Andreas du Bois, Sibylle Loibl, et al.. (2013). Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Research and Treatment. 139(3). 779–787. 19 indexed citations

Müller, Volkmar, Christoph Thomssen, Marcus Schmidt, et al.. (2010). Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC Cancer. 10(1). 430–430. 1 indexed citations

Herr, Daniel J., J. König, V. Heilmann, et al.. (2008). Prognostic Impact of Satellite-Lymphovascular Space Involvement in Early-Stage Cervical Cancer. Annals of Surgical Oncology. 16(1). 128–132. 24 indexed citations

Hancke, Katharina, V. Heilmann, Peter Straka, R. Kreienberg, & Christian Kurzeder. (2008). Pretreatment Staging of Cervical Cancer: Is Imaging Better Than Palpation?. Annals of Surgical Oncology. 15(10). 2856–2861. 46 indexed citations

Pfisterer, Jacobus, Andreas du Bois, Jalid Sehouli, et al.. (2006). The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Annals of Oncology. 17(10). 1568–1577. 50 indexed citations

Schmid, Peter, V. Heilmann, Carsten‐Oliver Schulz, et al.. (2005). Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. Journal of Cancer Research and Clinical Oncology. 131(9). 568–574. 12 indexed citations

Heilmann, V., Holm Eggemann, G. Heinrich, et al.. (2005). Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 753–753. 3 indexed citations

Hilpert, Felix, Alexander Burges, K Späthe, et al.. (2005). Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Supportive Care in Cancer. 13(10). 797–805. 58 indexed citations

10.

Schmid, Peter, C. Jehn, Holm Eggemann, et al.. (2005). Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Annals of Oncology. 16(10). 1624–1631. 29 indexed citations

11.

Schmid, Peter, Bernd Flath, V. Heilmann, et al.. (2005). Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study. Investigational New Drugs. 23(4). 349–356. 4 indexed citations

12.

Harter, P, G. P. Breitbach, B. Tanner, et al.. (2005). Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Journal of Clinical Oncology. 23(16_suppl). 5004–5004. 5 indexed citations

13.

Schmid, Peter, G Morack, V. Heilmann, et al.. (2004). Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study. Journal of Cancer Research and Clinical Oncology. 130(11). 657–663.

14.

Schmid, Peter, Carsten‐Oliver Schulz, Annette Dieing, et al.. (2004). Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Anti-Cancer Drugs. 16(1). 21–29. 14 indexed citations

15.

Sauer, Georg, et al.. (2003). Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion.. PubMed. 9(17). 6426–31. 45 indexed citations

16.

Greiner, Jochen, Mark Ringhoffer, Masanori Taniguchi, et al.. (2002). Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Experimental Hematology. 30(9). 1029–1035. 118 indexed citations

17.

Rieber, A., Hans‐Juergen Brambs, Andreas Gabelmann, et al.. (2002). Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. European Radiology. 12(7). 1711–1719. 169 indexed citations

18.

Klaes, Ruediger, Matthias Nees, Matthias Dürst, et al.. (2001). Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. International Journal of Cancer. 92(1). 9–17. 143 indexed citations

19.

Krämer, Stefan C., Johannes Görich, N. Rilinger, et al.. (1999). Interventionelle Behandlungsmöglichkeiten von Blutungen bei fortgeschrittenen Karzinomen der Cervix uteri. Der Radiologe. 39(9). 795–798. 4 indexed citations

20.

Tong, Xiaowen, et al.. (1994). Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Human Genetics. 93(6). 620–4. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact